RxDoctor Payments Data

Yamama Hafeez

Interventional Cardiology · Apple Valley, CANPI 1841684370

Payments from drug & device makers

$8,326in general payments, 2019–2025

Across 154 payments — averaging $54.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$2K
  • Boston Scientific$2K
  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$499
  • Biotronik Inc.$438
  • Bard Peripheral Vascular, Inc.$280
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$7,83594%
  • Education$4906%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,326 in reported general payments places this provider in the 45th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$218,487
Medicare patients
596
Services billed
2,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$62,576
BrilintaTicagrelor24$22,591
XareltoRivaroxaban12$8,703
Nifedipine ErNifedipine23$707
Amiodarone Hcl25$615
ClopidogrelClopidogrel Bisulfate104$602
Atorvastatin Calcium68$578
Carvedilol72$380
Metoprolol Succinate44$306
Losartan Potassium38$288
Furosemide34$196
Metoprolol Tartrate50$150
Amlodipine Besylate37$144
Lisinopril19$112
Hydrochlorothiazide15$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$196$22,59124 claims
Johnson & JohnsonXarelto$42$8,70312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →